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Abstract
Background: Public trust is central to the collection of genomic and health data and the sustainability of genomic
research. To merit trust, those involved in collecting and sharing data need to demonstrate they are trustworthy.
However, it is unclear what measures are most likely to demonstrate this.
Methods: We analyse the ‘Your DNA, Your Say’ online survey of public perspectives on genomic data sharing
including responses from 36,268 individuals across 22 low-, middle- and high-income countries, gathered in 15
languages. We examine how participants perceived the relative value of measures to demonstrate the
trustworthiness of those using donated DNA and/or medical information. We examine between-country variation
and present a consolidated ranking of measures.
Results: Providing transparent information about who will benefit from data access was the most important
measure to increase trust, endorsed by more than 50% of participants across 20 of 22 countries. It was followed by
the option to withdraw data and transparency about who is using data and why. Variation was found for the
importance of measures, notably information about sanctions for misuse of data—endorsed by 5% in India but
almost 60% in Japan. A clustering analysis suggests alignment between some countries in the assessment of
specific measures, such as the UK and Canada, Spain and Mexico and Portugal and Brazil. China and Russia are less
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: rm23@sanger.ac.uk
1Society and Ethics Research Group, Wellcome Connecting Science,
Wellcome Genome Campus, Cambridge CB10 1SA, UK
2Department of Public Health and Primary Care, University of Cambridge,
Cambridge CB2 0SR, UK
Full list of author information is available at the end of the article
Milne et al. Genome Medicine           (2021) 13:92 
https://doi.org/10.1186/s13073-021-00903-0
(Continued from previous page)
closely aligned with other countries in terms of the value of the measures presented.
Conclusions: Our findings highlight the importance of transparency about data use and about the goals and
potential benefits associated with data sharing, including to whom such benefits accrue. They show that members
of the public value knowing what benefits accrue from the use of data. The study highlights the importance of
locally sensitive measures to increase trust as genomic data sharing continues globally.
Background
The future of genomic medicine relies on the ability of
researchers and clinicians to access large quantities of
genomic and health data. The support of patients and
the public for the collection and use of data is central to
the success and sustainability of genomic research [1].
However, public willingness to share data and trust in
the bodies responsible for the collection and sharing of
genomic data varies between countries and between ac-
tors involved in the genomic data ecosystem [2, 3]. Trust
in the for-profit research sector and governments, for
example, is commonly lower than that in non-profit and
clinical organisations [4–7]. In this paper, we present
findings on public views of measures that may increase
trust by ensuring or demonstrating the trustworthiness
of the organisations, institutions and individuals working
with genomic datasets.
The shift in focus from trust to trustworthiness is an
important one, recognised in a growing body of work on
genomic medicine [2, 8]. Trust involves a relationship
between two actors with an expectation of an outcome
[9]. Discussion of trust often places the emphasis on the
one placing trust, whether a patient or a member of the
public. However, these individuals are placing trust that
another actor—for example a clinician, researcher or
company—is motivated to act to pursue a particular goal
[10]. It is here that trustworthiness is critical. If these ac-
tors are not trustworthy, trust is neither merited nor
meaningful. Trust misplaced in this way has the poten-
tial to harm both those who place their trust and those
who betray it, for example through long-term impact on
reputation or the loss of future research opportunities.
An emphasis on trustworthiness moves the focus away
from the public to those involved in collecting and using
data and presents an opportunity for the latter to act to
exhibit qualities that demonstrate that they are worthy
of trust [11]. The meaning of trustworthiness in practice,
however, remains unclear, including the activities or
measures that show that those collecting and using data
are worthy of trust [2, 12–14]. A number of features
exhibited by ‘trustworthy’ systems for genomic data have
been suggested. These include the importance of
establishing shared values and common goals and mo-
tives between researchers and participants or members
of the public involved in research. This may include
demonstrating a focus on the common good and the
equitable distribution of risks and benefits [15]. It may
also mean supporting research ethics measures such as
informed consent with robust governance that is respon-
sive to stakeholders, respectful, transparent, sustainable,
audited and regularly assessed, potentially combined
with legal protections [1, 16–19]. Further, work to
embed research in relation to local values and goals may
be particularly important in addressing potential distrust
arising from historical discrimination in healthcare and
research [10, 16].
This prior work identifies practices that are already in
place in at least some large genomic data initiatives and
those to which they and other initiatives might aspire—
some that might be new, others that may involve refine-
ment of existing activities. To date, however, discussions
of the trustworthiness of genomic and health data initia-
tives and their relationship with public trust have rarely
enabled comparisons between contexts, particularly
between countries [3, 5, 20]. This makes it difficult to
consider how transferable measures to establish trust-
worthiness might be and how they are differently valued
in different research contexts. Such an international
perspective is critical given the need for international
data sharing and has the potential to support the devel-
opment of policies for the sharing of genomic data
through initiatives like the Global Alliance for Genomics
and Health (GA4GH) [21].
We provide an international perspective through an
analysis of the ‘Your DNA, Your Say’ online survey, a
study of public perspectives on genomic data sharing
that draws on responses from 36,268 individuals across
22 low-, middle- and high-income countries, gathered in
15 languages. We have previously reported on variations
in trust within and between these countries, and the re-
lationship between trust and willingness to donate DNA
and health information [6, 22]. Here we focus in detail
on responses to a question asking participants, who
would consider donating DNA or medical information,
which measures would help them trust those with whom
their data may be shared. Our aim with this question is
to draw out how current and potential practices contrib-
ute to demonstrating the trustworthiness of data users.
We analyse how participants perceived the relative value
of these measures, how this varied across the 22
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countries of the study, and provide a consolidated rank-
ing of the measures. We then examine similarities and
differences between countries, clustering countries that
share similar perspectives on the value of these mea-
sures. This allows us to consider the implications of our
findings for data sharing policies and their applicability
across social, cultural and regulatory contexts.
Methods
Sample
Via the international network of researchers affiliated
with the GA4GH, the research team invited social sci-
ence, genetic counselling, bioethics and policy collabora-
tors around the world to participate in conducting the
‘Your DNA, Your Say’ project, either supporting recruit-
ment into the project and/or translating the survey. For
all countries except Japan, Pakistan and India (see
below), data were collected using a cross-sectional online
survey with participants recruited via market research
company Dynata. We aimed to recruit a sample that was
as representative as possible of each country’s population
with regard to gender, age and education level. To this
end, participant characteristics were monitored during
recruitment to proactively include individuals from
under-represented population subgroups. Sociodemo-
graphic characteristics of participants from each country
are shown in Additional file 1: Table S1 and Additional
file 1: Figures S1-S5.
In Japan, participants were recruited through a survey
research company (Cross Marketing) using the same
approach. In Pakistan and India, recruitment was con-
ducted by market research companies (Foresight and
Maction, respectively), and methods were varied to ac-
count for lower Internet access. In Pakistan, participants
completed the questionnaire on a tablet at a central
location rather than at home. In India, participants
completed the questionnaire on tablets provided by field
researchers. Completed surveys were gathered from
Argentina, Australia, Belgium, Brazil, Canada, China,
Egypt, France, Germany, India, Italy, Japan, Mexico,
Pakistan, Poland, Portugal, Russia, Spain, Sweden,
Switzerland, UK and the USA. Participants were paid a
small financial reward (<£1) for participating, and due to
the nature of the recruitment, there are no details on the
non-response rate. The study methodology, design, re-
cruitment strategy, limitations and process of data col-
lection are described separately [23].
Measures
Our onl ine survey can be accessed from www.
YourDNAYourSay.org. It contains 29 questions; back-
ground information about the landscape of genomic re-
search and data sharing is provided via nine films that
sit within the survey (see Fig. 1); no prior knowledge
about genomics is required to participate.
In this paper, we analyse a question that asked partici-
pants what information would help them to trust the
people asking them to donate DNA information and/or
medical information. As shown in Table 1, this question
allowed for a structured response, with participants
selecting from a range of measures suggested in existing
work on the ethics and governance of genomic data plat-
forms. These measures include practices already in place
in some, if not many, genomic data initiatives, and those
that are more aspirational [24].
One feature of relevance to this question is how we
presented information about motives associated with
data donation and collection; in the survey films and
text, we articulated how different actors may obtain and
be motivated by disparate multiple and divergent bene-
fits from the use of donated data. When asking whether
participants would be willing to donate their DNA and
medical information to medical doctors for use in mak-
ing a diagnosis in another patient, they were told:
‘Whilst there might be benefits to patients from this
work, medical doctors might benefit too. For example,
through getting more diagnoses for patients and there-
fore being better at their jobs or getting scientific publi-
cations’. When asking whether participants would be
willing to donate their DNA and medical information
for use by non-profit researchers doing research, for ex-
ample on how DNA links to disease, they were told:
‘There might be benefits to society from this work. But
also, individual researchers and organisations might
benefit too. For example, individual researchers could
advance their career and organisations bring in new
funding’. Then finally, when asking whether participants
would be willing to donate their DNA and medical in-
formation for use by for-profit researchers doing re-
search, for example, developing new medicines, they
were told: ‘There might be benefits to society from this
work. But also, individual researchers and organisations
might benefit too. For example, individual researchers
might advance their career and companies make a
profit’. Thus, we were explicit in giving examples of how
access and use of data might be motivated by, and lead
to, the accrual of personal and organisational, as well as
societal and clinical benefit.
We treat countries as the unit of analysis rather than
individuals, deriving country-level variables from data
collected at the individual level. We use participant-
provided information on country of residence and on
which measures would help support trust. We focus on
those who said that they would potentially be willing to
donate DNA or medical information (n=29,814); partici-
pants who were not willing to donate were excluded
from further analyses. The breakdown of refusals by
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country is shown in Additional file 1: Table S2 (range
4% (India) to 33% (Japan); mean 16.6%).
Analysis
Country-level responses
We converted individual responses to this question into
a country-level ranked list of these measures from most
to least important. This ranking is the variable of inter-
est. We also calculated a ‘global’ ranked list based on
overall responses. This was compared with a consensus-
generated list derived as part of the analysis (described
below).
Consolidated ranking across countries
We used the top-k approach [25] to identify common
top-ranking responses across countries and to generate a
consolidated consensus rank for the measures. We cal-
culated the consensus ranking for the measures using
three algorithms (Borda, Markov Chain – majority rule,
and the Order Explicit Algorithm) using the TopKLists
package [26].
Correlation of responses between countries
The rank of the different measures was calculated for
each country. We examined pair-wise correlations be-
tween all countries, estimated using Kendall’s tau-b
Fig. 1 The appearance of the online Your DNA, Your Say survey (Arabic version). The Your DNA, Your Say questionnaire was presented in 15
languages. Background information on genomic research and data sharing was provided by nine films
Table 1 YDYS survey question relating to measures that would help people to trust recipients of donated DNA/medical information
Q: What information would help you to trust the
people asking you to donate DNA information
and/or medical information? (choose all that apply)
• Transparent information about WHO will benefit from the data access
• Transparent information about HOW others will benefit personally, professionally and
commercially from the data access
• A website that clearly explains the pros and cons of data access
• The option to opt out of having your information accessed by other researchers
• The option to withdraw your information in the future
• Biographies and photos of the sorts of researchers who would access the data
• Knowing exactly who is using your information, and for what purpose
• The ability to access your own DNA information and/or medical information
• Being able to communicate directly with gatekeepers of my DNA information and/or medical
information
• Details about the sanctions applicable if my data is misused by others
• Other, please provide:
• I would not donate my DNA information and/or medical information
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coefficient, which permits estimation of correlations be-
tween non-parametric data with ties. In total, there are
231 unique pair-wise correlations; we used a Bonferroni
correction to guide interpretation of significance of cor-
relations. We used the Superheat package to visualise
the pair-wise correlations and generate a cluster dendro-
gram illustrating similarities between countries [27].
Results
The percentage of participants endorsing each measure
to increase trust in the recipients of donated data is
shown for the overall sample and by country in Table 2
and Fig. 2. Measures are ordered by ranking in the over-
all sample.
The figure and table illustrate that there is substantial
variability between countries in terms of the ranking of
the different measures. This is shown further in the box-
plots in Fig. 3.
For all but two countries, provision of transparent in-
formation about who will benefit from data access was
endorsed by a majority (i.e. > 50%) of participants, in-
cluding more than 70% of respondents in Egypt,
Argentina, Portugal and Switzerland, although China
was an extreme outlier with only 32% of respondents en-
dorsing this. Overall, the option to withdraw information
in the future was the second most endorsed measure
across the sample, with the greatest number of respon-
dents endorsing this option in Australia, Canada,
Switzerland and the UK, but only 31% in Egypt.
Endorsement was most variable for details about sanc-
tions for misuse of data, ranging from 5% in India to
almost 60% in Japan, where it was the most chosen op-
tion. Direct interaction with gatekeepers was a divisive
measure with many outliers both above (Australia,
Russia, Portugal) and below (Italy, Japan, India) the aver-
age endorsement.
Countries varied in the number of measures that were
endorsed by a majority of respondents. While five or
more measures were endorsed by more than 50% of re-
spondents in the UK, Portugal, Canada and Australia,
only one—the ability to opt out of having information
access by other researchers—was endorsed by an equiva-
lent proportion of respondents in China.
Consolidated ranking
The consensus results from the top-k approach (Table 3)
confirm the rank order obtained from the overall ranking
based on percentage endorsement (from most to least im-
portant). The only exception is that the ability to access
one’s own DNA/or medical information is ranked one
place above details about sanctions (as opposed to one
rank lower based on percentage endorsement).
Correlation of responses between countries
The pair-wise correlation estimates for all country pairs
are shown in Fig. 4. Pairwise correlations are shown in
Table S3 for all estimates greater than or equal to 0.9.
The two strongest correlations, with p values below the
Bonferroni-corrected threshold of 0.0002, were between
Mexico and Spain, and France and Poland (both at
0.98). The lowest correlation (data not shown) was be-
tween Russia and India, with an estimate of − 0.16.
Overall, the heatmap and dendrogram in Fig. 4 show
groups of countries for which the rankings of these mea-
sures were very similar and that form specific clades.
Similarity is not necessarily related to geographical prox-
imity, as for example in the similarity of Spain and
Mexico or the UK and Australia. Some countries, not-
ably China and Russia and to some extent India, Egypt,
and Japan have consistently lower correlations with most
other countries and are linked only at higher levels of
the dendrogram—with China and Russia forming a sep-
arate, distinct clade from the other 19 countries in the
sample.
Discussion
Transparency about aspirations and access
Across countries, measures to demonstrate the trust-
worthiness of the actors asking for and sharing genomic
and health data should focus on transparency about the
potential benefits of research, to whom such benefits will
accrue and how this will happen. That is, it is not just
about describing the general promise and potential of re-
search—such as a benefit to future patients—but also
providing an outline of how these benefits will be rea-
lised through research. While existing work has sug-
gested the importance of a clear common goal in
building trusting relationships with potential data do-
nors, our findings are the first to emphasise the global
importance of being clear in this message [16, 17].
It is also important to note, however, that transparency
is not limited to outlining expected societal benefits (e.g.
finding treatment to a disease) and how they are to be
realised. A recurrent feature of research on public trust
has been the low levels of trust associated with for-profit
or private sector actors, particularly in relation to finan-
cial profits for shareholders [5–7]. Yet the benefits mo-
tivating the use of research or clinical access to large
datasets are not only pecuniary. A further step towards
demonstrating trustworthiness, and ‘respectful interac-
tions’ [17] around data would be for potential data users
to reflect on and acknowledge their multiple interests in
and motivations for collecting and using health data, and
to be transparent about these. Such transparency may
enable data donors to more clearly understand what mo-
tivates the use of data, and thus make a more confident
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assessment of a data users’ motivation and the extent to
which it reflects a desirable or common goal [10, 15].
A further role of transparency relates to the responsi-
bility of those collecting and using genomic data to pro-
vide clear and accessible information on who is using
data and for what purposes [28]. Our work suggests that
such transparency is indeed an important feature of
trustworthy data stewardship across the 22 countries
studied. It also draws attention to the potential
importance of familiarity, not just with genetics—as we
have highlighted elsewhere—but with the individuals or
organisations responsible for genomic data [22, 29].
Our findings suggest, however, that the value of open-
ness does not necessarily extend to individuals’ ability to
access their own DNA and health data. Such direct ac-
cess as a reciprocation of individual contributions was
comparatively less important to participants as a meas-
ure to increase trust. Thus, while access to data may be
Fig. 2 Measures to help trust recipients of donated DNA/medical information. Percentage of participants endorsing each measure proposed to
help to trust recipients of donated DNA/medical information, overall and by country
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valued by some participants in light of personal interest
and perceived personal utility, communicating the po-
tential for such access is not necessarily likely to demon-
strate the trustworthiness of actors using of genomic
data.
Data rights and regulation
While the measures discussed above concentrate on the
goals and roles of genomic research and transparency
about access to data, the high ranking of withdrawal and
opt outs from data use highlights the importance and
value of demonstrating adherence to research ethics
frameworks, including informed consent. The right to
withdraw, for example, is protected and reinforced
throughout clinical research ethics guidance as well as
data protection law (e.g. General Data Protection
Regulation), but presents specific challenges in the case
of long-term genomics research [1, 30]. Our findings
suggest the value of efforts to reinforce and protect this
right, even as data are de-identified and shared, making
it clear to data donors that this right exists, but also to
be open about its limits and the difficulties associated
with tracking shared de-identified data.
The comparatively lesser importance attributed to
sanctions for data misuse suggests that regulation and
enforcement measures to prevent misuse and exploit-
ation may be important to prevent a loss of trust but
make a smaller contribution to demonstrating trust-
worthiness [14]. Respondents across all countries were
less likely to value being able to communicate directly
with the gatekeepers of genomic and health data collec-
tions, or to be able to access websites about data sharing
or see profiles of researchers. The first is interesting,
given the importance placed by policy-makers on identi-
fying those responsible for data in regulatory interven-
tions such as European Union’s General Data Protection
Regulation (GDPR). The latter suggests that, a website
might be of informational value to some, but that efforts
to build trust may need more proactive engagement with
data donors. This concords with work that suggests de-
tails about individual data users may have little value to
data donors without knowledge of why that individual is
trustworthy, returning discussion to the measures out-
lined above [31].
Cross-country consistency and variation
While the overall picture provided by both the consoli-
dated ranking and the individual country rankings
Fig. 3 Percentage of participants endorsing each measure by country. Boxplots show the percentage endorsing each measure per country,
showing the variability associated with each option. Outliers are labelled
Table 3 Consolidated ranking of measures to increase trust
based on the top-k approach
1. Transparent information about WHO will benefit from the data
access
2. The option to withdraw your information in the future
3. Knowing exactly who is using your information, and for what
purpose
4. Transparent information about HOW others will benefit personally,
professionally and commercially from the data access
5. The option to opt out of having your information accessed by other
researchers
6. The ability to access your own DNA and/or medical information
7. Details about the sanctions applicable if my data is misused by
others
8. A website that clearly explains the pros and cons of data access
9. Being able to communicate directly with gatekeepers of my DNA
and/or medical information
10. Biographies and photos of the sorts of researchers who would
access the data
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grouped in Figs. 2 and 3 are consistent, our data show
variation between countries in their views of measures
to enhance trust. The option of communicating with
gatekeepers, for example, was selected by a far higher
proportion of respondents in Australia, Portugal and
Russia than in Japan, Italy or India. Variation is also seen
among countries that share, to an extent, legal and
decision-making frameworks relevant to genomic data,
such as member states of the European Union—al-
though all ten European countries in the sample fall
within the same broad clade of 17 countries in Fig. 4,
each often has greatest similarity with countries outside
the bloc. At a European level, these findings may con-
tribute to the exploration of national variation in the im-
plementation of regulation and legal safeguards derived
from the GDPR [32].
Further patterns of consistency and divergence can be
seen in the detail of the dendrogram. Some results ap-
pear intuitive while others are more unexpected. For ex-
ample, the clade in which the UK and Australia cluster
may be anticipated given their (partly) shared histories,
and similar governance and social healthcare systems.
The connection between France and Switzerland might
also be expected, particularly among Francophone re-
spondents. Other results are less expected —it is inter-
esting that the USA is not as closely associated
with some countries as might be anticipated given geo-
graphic proximity and/or shared histories, such as
Canada or the UK. The clade that brings together
India and Egypt with Japan, Russia and China is also
suggestive of interesting directions for further
investigation.
As a whole, the patterns of consistency and variation
shown here provide nuance to discussions of trust-
worthiness and present challenges to those developing
standards and governance models to facilitate the inter-
national sharing of genomic and health data. Most sig-
nificantly, they suggest that while it is important to work
to establish codes of conduct and demonstrate shared
values and goals between researchers and data donors,
conclusions from such work can only be tentatively ex-
tended across national settings. They further point to
Fig. 4 Heatmap of pair-wise correlation estimates. The strength of the pairwise correlation is indicated by the colour of the square, from dark
blue to yellow. The dendrogram indicates clustering among countries where responses were closely aligned
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the need for detailed comparative work, including quali-
tative studies, to understand how and why trustworthi-
ness can be demonstrated by the individuals and
institutions using genomic and health data.
Limitations
The limitations of the study and design have been pub-
lished separately [24]. As an exploratory cross-sectional
online survey, the study is limited in that it captures
intended behaviour at a single time point. Three particu-
lar limitations are important to note. Firstly, our analysis
is limited to those who would be willing to consider do-
nating their DNA or health information for research.
While this includes the majority of the sample, it cannot
tell us which measures to increase trust may be more
valued by those who definitely will not donate. Second,
although the survey was translated and back-translated,
nuances of language and culture may affect how partici-
pants interpret the options presented. Finally, measures
deemed as important in this study, while important and
likely necessary, are unlikely to be sufficient on their
own to assure potential donors of DNA and health data
of the trustworthiness of actors involved in collecting,
using and sharing data.
Conclusions
The analysis of responses across the 22 countries in-
cluded in the Your DNA, Your Say survey suggests
practical findings related to demonstrating the trust-
worthiness of genomic data initiatives, and directions for
further research to explore global public perspectives in
more detail. They show the importance of research eth-
ics principles related to the right to withdraw, but sug-
gest that legal and regulatory controls may be more
important in preventing the loss of trust than in rebuild-
ing it. While highlighting significant variation between
countries, they emphasise the importance of transpar-
ency about data uses, but particularly about the goals of
data collection, and the potential benefits for patients
and society, and for data users themselves.
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